Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.

Biotech Giants' R&D Race: Who Leads in Innovation?

__timestampArrowhead Pharmaceuticals, Inc.Neurocrine Biosciences, Inc.
Wednesday, January 1, 20142313805046425000
Thursday, January 1, 20155741014781491000
Friday, January 1, 20164145445294291000
Sunday, January 1, 201731690298121827000
Monday, January 1, 201852968505160524000
Tuesday, January 1, 201981048686200000000
Wednesday, January 1, 2020128874979275000000
Friday, January 1, 2021206342000328100000
Saturday, January 1, 2022297307000463800000
Sunday, January 1, 2023353188000565000000
Monday, January 1, 2024505870000731100000
Loading chart...

Data in motion

Innovation in Biotech: A Comparative Analysis

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc. have demonstrated significant investments in R&D, reflecting their dedication to advancing medical science. From 2014 to 2023, Neurocrine Biosciences increased its R&D spending by approximately 1,117%, peaking in 2023. Meanwhile, Arrowhead Pharmaceuticals saw a staggering 2,085% increase in the same period, with a notable jump in 2024, despite missing data for Neurocrine in that year. This trend highlights Arrowhead's aggressive push towards innovation, potentially positioning it as a leader in the biotech sector. As these companies continue to prioritize R&D, their efforts could lead to groundbreaking treatments and therapies, shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025